Analysts' Revenue Estimates For Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Are Surging Higher

Yahoo FinanceApr 20 21:58

Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald

Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald

Dow JonesApr 19 22:53

Cantor Fitzgerald Company: The Taysha Gene Therapies (TSHA.US) rating was reaffirmed and adjusted from an increase to an increase in holdings rating, with a target price of $7.00.

Cantor Fitzgerald Company: The Taysha Gene Therapies (TSHA.US) rating was reaffirmed and adjusted from an increase to an increase in holdings rating, with a target price of $7.00.

Zhitong FinanceApr 18 21:41

Cantor Fitzgerald Reiterates Overweight on Taysha Gene Therapies, Maintains $7 Price Target

Cantor Fitzgerald analyst Kristen Kluska reiterates Taysha Gene Therapies with a Overweight and maintains $7 price target.

Analyst UpgradesApr 18 21:37

Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler

Seeking AlphaApr 12 23:34

Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Friday. Shares of Applied Digital Corporation (NASDAQ:APLD) fell sharply in today's pre-market trading after

BenzingaApr 12 20:04